Oak Ridge Investments LLC Raises Stock Position in Urogen Pharma $URGN

Key Points

• Oak Ridge Investments LLC has increased its position in Urogen Pharma by 20.5% during the first quarter, now owning 73,704 shares worth $815,000.
• Several hedge funds have also recently invested in Urogen Pharma, with institutional investors collectively owning 91.29% of the company's stock.
• Urogen Pharma reported a net earnings miss for the last quarter, posting ($1.05) earnings per share, below the consensus estimate of ($0.82).

Oak Ridge Investments LLC grew its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 20.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 73,704 shares of the company's stock after purchasing an additional 12,539 shares during the period. Oak Ridge Investments LLC owned about 0.16% of Urogen Pharma worth $815,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of URGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Urogen Pharma by 4.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock worth $231,000 after purchasing an additional 969 shares during the period. Rhumbline Advisers grew its stake in shares of Urogen Pharma by 4.3% in the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after buying an additional 2,196 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Urogen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after purchasing an additional 2,727 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Urogen Pharma by 24.6% in the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after buying an additional 3,920 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Urogen Pharma by 9.3% during the fourth quarter. Ameriprise Financial Inc. now owns 49,153 shares of the company's stock worth $523,000 after purchasing an additional 4,188 shares during the period. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Trading Up 2.1%

Shares of URGN traded up $0.39 on Wednesday, reaching $19.31. The company's stock had a trading volume of 817,045 shares, compared to its average volume of 1,165,014. The stock has a market capitalization of $893.28 million, a PE ratio of -5.82 and a beta of 1.12. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.01. The firm has a fifty day moving average of $16.18 and a 200-day moving average of $11.82.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to analysts' expectations of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, equities analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,522 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. This represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This trade represents a 6.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,833 shares of company stock worth $457,467 over the last three months. 4.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on URGN shares. D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a report on Tuesday, August 5th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. HC Wainwright reduced their price target on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Finally, The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.00.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.